Supplementary Figures 1 - 8, Table 1 from Positron Emission Tomography Imaging with <sup>18</sup>F-Labeled Z<i><sub>HER2:2891</sub></i> Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies

<p>PDF file - 999K, Supplementary Figure S1: Scheme of FASTlab-compatible automated synthesis of 18FGE-226. Supplementary Figure S2. Interaction of GE-226 with HER2 as determined by Surface Plasmon Resonance. Supplementary Figure S3: Tracer uptake is dependent on specific radioactivity in SKOV-3 cells. Supplementary Figure S4: Plasma metabolite profile and tissue pharmacokinetics of 18FGE-226. Supplementary Figure S5: Specificity of 18FGE-226 receptor interaction determined by blocking studies, differential tumor uptake and kinetic modeling. Supplementary Figure S6: Influence of trastuzumab on heart and kidney pharmacokinetics. Supplementary Figure S7: HER2 expression analysis and genomic DNA sequencing in relation to uptake rate constants in trastuzumab-treated or control xenografts. Supplementary Figure S8: 18FGE-226 uptake and HER2 expression in response to HSP90 inhibition. Supplementary Table S1: Biodistribution of 18FGE-226 in tumor-bearing BALB/c nude mice. Supplementary Method: Procedures for synthesis of fluorescein labeled GE-226, surface plasmon resonance, western blotting, biodistribution, metabolic stability, small animal models for fluorescent GE-226 experiments, immunohistochemistry, ELISA and sequencing.</p>